GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Operating Margin %

AMRX (Amneal Pharmaceuticals) Operating Margin % : 10.89% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Amneal Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $76 Mil. Amneal Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $702 Mil. Therefore, Amneal Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2024 was 10.89%.

The historical rank and industry rank for Amneal Pharmaceuticals's Operating Margin % or its related term are showing as below:

AMRX' s Operating Margin % Range Over the Past 10 Years
Min: -8.54   Med: 9.32   Max: 26.9
Current: 10.4


AMRX's Operating Margin % is ranked better than
60.8% of 995 companies
in the Drug Manufacturers industry
Industry Median: 6.62 vs AMRX: 10.40

Amneal Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Amneal Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $76 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $279 Mil.


Amneal Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Amneal Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Operating Margin % Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -8.54 5.57 9.26 8.54 9.37

Amneal Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.34 5.86 12.63 11.82 10.89

Competitive Comparison of Amneal Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Operating Margin % falls into.



Amneal Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Amneal Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=224.25 / 2393.607
=9.37 %

Amneal Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=76.475 / 702.468
=10.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amneal Pharmaceuticals  (NAS:AMRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Amneal Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Executives
Deborah M. Autor director C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
John Kiely director C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jason B. Daly officer: SVP, Chief Legal Officer 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Andrew S Boyer officer: Exec VP, Comm Optns C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Nikita Shah officer: SVP, Chief HR Officer C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin officer: See Remarks 4 PARK LANE, MADISON NJ 07940
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco officer: SVP, Specialty Commercial 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862